Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT07855497
Active, not recruiting Not applicable

Efficacy and Safety of Second-Line Helicobacter Pylori Eradication

NCT07855497 · tracked via the Priya Life Science South Korea tracker
Sponsor
Seoul National University Bundang Hospital
Phase
Not applicable
Started
2021-02-01
Last updated
2026-10-02

Condition(s) studied

HELICOBACTER PYLORI INFECTIONS

Investigational drug(s) / intervention(s)

P-CAB-BM quadruple regimen →Moxifloxacin triple regimen →

P-CAB-BM quadruple regimen: Esomeprazole, amoxicillin, and moxifloxacin

Moxifloxacin triple regimen: Tegoprazan, amoxicillin, moxifloxacin, and bismuth

Study summary

Subjects with persistent H. pylori infection after first-line treatment failure receives either a 14-day PPI-based moxifloxacin triple regimen (esomeprazole, amoxicillin, and moxifloxacin) or a 14-day P-CAB-bismuth-containing moxifloxacin quadruple regimen (tegoprazan, amoxicillin, moxifloxacin, and bismuth).

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients with persistent H. pylori infection after failure of first-line eradication therapy * H. pylori infection was confirmed by at least one positive result on the 13C-urea breath test (UBT), rapid urease test, or histology * Patients who provided written informed consent and who are able to complete symptom questionnaires Exclusion Criteria: * Individuals younger than 19 years, pregnant or lactating females, patients with previous total gastrectomy, severe systemic diseases, recent use of antibiotics or acid-suppressive medications, drug allergies, or other conditions considered inappropriate by the investigators

Primary outcome measure(s)

  • The efficacy of H. pylori eradication — From enrollment to the end of treatment at 4 weeks
    Success rate of H. pylori eradication of each regimen (ITT and PP)

Trial sites (1)

FacilityCityRegionStatus
Seoul National University Bundang Hospital Seongnam-si Gyeonggi-do

More Seoul National University Bundang Hospital trials in South Korea

Pepsinogen II and Helicobacter Pylori Test in Gastric Cancer Active, not recruiting
A Study on the Effects of A2 Milk on Gut Beneficial Bacteria Growth and Digestion Improvement Active, not recruiting
Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism Recruiting
Dual-chamber Patient-controlled Analgesia for Postoperative Recovery Recruiting
Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07855497 on ClinicalTrials.gov ↗ ← All trials in South Korea